International Assets Investment Management LLC Acquires 18,111 Shares of Organon & Co. (NYSE:OGN)

International Assets Investment Management LLC increased its holdings in Organon & Co. (NYSE:OGN) by 1,851.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 19,089 shares of the company’s stock after purchasing an additional 18,111 shares during the quarter. International Assets Investment Management LLC’s holdings in Organon & Co. were worth $365,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc increased its position in shares of Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock worth $25,000 after purchasing an additional 805 shares in the last quarter. William B. Walkup & Associates Inc. acquired a new position in shares of Organon & Co. during the second quarter worth $31,000. Atlas Capital Advisors LLC increased its position in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after purchasing an additional 2,147 shares in the last quarter. Fidelis Capital Partners LLC acquired a new position in shares of Organon & Co. during the first quarter worth $43,000. Finally, Rothschild Investment LLC acquired a new position in shares of Organon & Co. during the second quarter worth $54,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Shares of OGN opened at $15.78 on Thursday. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.17. The firm has a market capitalization of $4.06 billion, a PE ratio of 3.13, a price-to-earnings-growth ratio of 0.76 and a beta of 0.84. The company’s fifty day moving average price is $19.14 and its 200-day moving average price is $20.11.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the company posted $0.78 earnings per share. Organon & Co.’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, equities research analysts predict that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.10%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.